Anti-Infliximab (REMICADE) Quantitative ELISA Assay Kit
The Anti-Infliximab (REMICADE) Quantitative ELISA Assay Kit is For Research Use Only
Size: 12 x 8 wells
Sensitivity: 3.125 ng/mL
Standard Range: 0 – 300 ng/mL
Incubation Time: 2 hour 20 minutes
Sample Type: Serum, Plasma
Sample Size: 20 µL
Alternative Name: Remicade
Controls Included
Assay Background
Infliximab is a tumor necrosis factor (TNFa) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. TN Fa isa key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signaling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TN Fa, infliximab disrupts the interaction of TNFa with its receptors and may also cause lysis of cells that produce TNFa. Infliximab is an IgG1 K monoclonal antibody that binds to soluble and transmembrane forms of TNFa with high affinity to disrupt the pro-inflammatory cascade signaling. Binding of the antibody to TN Fa prevents TN Fa from interacting with its receptors. Infliximab does not neutralize TN Fa (lymphotoxin-a), a related cytokine that utilizes the same receptors as TN Fa. Blocked actions of TN Fa further leads to downregulation of local and systemic pro-inflammatory cytokines (i.e. IL-1, IL-6), reduction of lymphocyte and leukocyte migration to sites of inflammation, induction of apoptosis of TNF-producing cells (i.e. activated monocytes and T lymphocytes), increased levels of nuclear factor-KB, inhibitor, and reduction of reduction of endothelial adhesion molecules and acute phase proteins. Its inhibitory actions on TN Fa was demonstrated in human fibroblasts, endothelial cells, neutrophils, B and T lymphocytes and epithelial cells. Infliximab also attenuates the production of tissue degrading enzymes synthesized by synoviocytes and/or chondrocytes.
Assay Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the drug infliximab. After incubation, the wells are washed. Then, horse radish-peroxidase (HRP) conjugated probe is added and binds to infliximab antibodies captured by the drug infliximab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of infliximab antibodies in the sample or standard. Results of samples can be determined directly using the standard curve.
Related Products
Anti-Infliximab (Remicade) ELISA Assay Kit
Total Infliximab ELISA Assay
Infliximab ELISA mAb-based Assay
